Svenska
MENUMENU

IMMray™ PanCan-d

Early detection of pancreatic cancer for increased survival rates

IMMrayTM PanCan-d is a unique blood test for the early detection of pancreatic cancer that has the potential to dramatically increase patient survival rates: from 5-8% to up to 49%. Our retrospective studies show that the test is able to detect stage I and stage II pancreatic cancer with an accuracy of 96%. A test with such a high level of accuracy would give clinicians a much greater chance of finding the cancer when it is still resectable by surgical procedures.

Click on image below for larger size.

Workflow

A standard patient blood sample is taken by the clinician and sent to the laboratory. At the laboratory, patient serum samples are applied on to the IMMray PanCan-d microarray that has room for up to 14 patient samples. Each microarray generates a biomarker signature that is evaluated for pancreatic cancer using advanced bioinformatics and complex software algorithms, after scanning with a standard fluorescent scanner.

IMMray PanCan-d has the potential to address several unmet clinical needs:

  1. Screening of high-risk groups i.e. familial/hereditary pancreatic cancer
  2. Testing of new onset diabetes type II patients over 50 years who suffer a 6-8 times increased risk of developing pancreatic cancer within 1-3 years
  3. Testing of patients with vague symptom profiles were the clinicans suspects, or wants to rule out, pancreatic cancer

IMMray PanCan-d is currently undergoing a prospective validation study to confirm our findings before market introduction. We are very interested in getting into contact with high-risk individuals with hereditary pancreatic cancer in the family.

References:

  1. Pancreatic registry in Japan – 20 years of experience, 2004.
  2. Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
  3. Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
  4. Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
  5. Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
  6. Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018 Aug 14. doi: 10.1200/JCO.2017.77.6658. 
Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports